1.This Act may be cited as the
Endocrine-Disrupting Chemicals
Exposure Elimination Act of 2011
.
2.The table of contents
of this Act is as follows:
Sec. 1. Short title.
Sec. 2. Table of contents.
Sec. 3. Findings.
Sec. 4. Definitions.
Sec. 5. Tiering applicable to levels of evidence and
concern.
Title I—Research on endocrine-disrupting chemicals
Sec. 101. National toxicology program activities.
Sec. 102. Research program of national institute of
environmental health sciences.
Title II—Reducing exposure to endocrine-disrupting
chemicals
Sec. 201. Federal agency action.
Sec. 202. Citizen suits.
Title III—Training
Sec. 301. Training in fields related to the prevention of
endocrine disruption.
Title IV—Miscellaneous
Sec. 401. Authorization of appropriations.
3.The Congress finds as follows:
(1)There is growing
evidence that the human endocrine system is extremely sensitive to particular
chemicals.
(2)Numerous studies
show links between particular chemicals and hormone functions in animals and in
humans, and those links have been further connected to numerous
disorders.
(3)A
targeted research and evaluation program on suspected endocrine-disrupting
chemicals would establish greater scientific certainty with respect to the
linkage of particular chemicals with endocrine system effects.
(4)Credible linkages
established by this research will be the basis for regulation under authorities
including—
(A)the Federal Food,
Drug, and Cosmetic Act;
(B)the Toxic
Substances Control Act;
(C)the Safe Drinking
Water Act;
(D)the Food Quality
Protection Act;
(E)the Clean Air
Act;
(F)the Clean Water
Act; and
(G)the Federal
Insecticide, Fungicide, and Rodenticide Act.
(5)Such research,
information availability, and scientific perspective would also promote
voluntary actions to reduce exposure to these harmful chemicals through market
forces.
(6)There is a need to
educate the public on the results of research on endocrine-disrupting chemicals
so that manufacturers, processors, retailers, and individual consumers can make
informed decisions about potential exposure to harmful chemicals.
(7)People should be
protected from chemicals that are found to have endocrine-disrupting
effects.
(8)Animal testing should be reduced to the
minimum necessary with the goal of transitioning to a predominantly nonanimal
paradigm as articulated in the 2007 National Research Council report
Toxicity Testing in the Twenty-First Century: A Vision and a
Strategy.
4.In this Act:
(1)The term
chemical means an individual chemical, a combination of chemicals,
or a mixture of chemicals.
(2)The term
Director means the Director of the National Institute of
Environmental Health Sciences.
(3)The term
endocrine-disrupting chemical means a chemical that interrupts,
alters, interferes with, disturbs, or otherwise changes the human endocrine
system or cell functioning.
(4)The term
Endocrine Disruption Expert Panel, Expert Panel, or
Panel means the Endocrine Disruption Expert Panel established
under section 101(a)(2).
5.Tiering
applicable to levels of evidence and concernIn identifying, determining, or making a
finding with respect to a level of evidence or a level of concern under this
Act (including sections 101(a)(3), 101(a)(4), 101(b)(2)(C), and 201(a)(2)(B)),
the Director or the Expert Panel, as applicable, shall select from among the
following levels:
(1)High.
(2)Substantial.
(3)Minimal.
(4)None.
<enum>I</enum><header>Research on
endocrine-disrupting chemicals</header>
<section id="H3C764B8AEB4544788BAC1FDFDE6AA02C"><enum>101.</enum><header>National
toxicology program activities</header>
<subsection id="H88385261ECD542AE94AE65BD4577D9BC"><enum>(a)</enum><header>In
general</header><text display-inline="yes-display-inline">As part of the
National Toxicology Program, the Director, in consultation with the National
Toxicology Program Board of Scientific Counselors (or any successor board or
committee), shall—</text>
<paragraph id="H31107E95EFF2409D9FC8508FD06E10B0"><enum>(1)</enum><text display-inline="yes-display-inline">establish and implement a research program
designed to strengthen the scientific basis of information used by Federal
agencies to understand the effects of, and reduce human exposure to,
endocrine-disrupting chemicals;</text>
</paragraph><paragraph id="HBC7E47D00F8A4F7BBCBDC60EFAA31BDE"><enum>(2)</enum><text>establish (subject
to subsection (b)(1)) an Endocrine Disruption Expert Panel and direct the Panel
to consider and report to the Director on issues related to identification,
classification, or evaluation of endocrine-disrupting chemicals as specified in
subsection (b)(2);</text>
</paragraph><paragraph id="H0961C2D72D5B416CA62D2034B5079EA4"><enum>(3)</enum><text>for each chemical
determined by the Director to be a potential or actual endocrine-disrupting
chemical—</text>
<subparagraph id="H1D00218F63FA42E6AD08FF685AE10C2D"><enum>(A)</enum><text>identify the level
of evidence that such chemical is or may be an endocrine-disrupting
chemical;</text>
</subparagraph><subparagraph id="H94D3FA4081F74BDDB2BE768E32A6BE8A"><enum>(B)</enum><text>identify the level
of concern that such chemical may disrupt the human endocrine system;
and</text>
</subparagraph><subparagraph id="H3D55978041E24C8A973755AA140E4498"><enum>(C)</enum><text>identify the
pathways of exposure to the chemical for humans and animals; and</text>
</subparagraph></paragraph><paragraph id="H1D26E810DECE4803A97808840A7C22E8"><enum>(4)</enum><text>not later than 2
years after the date of the enactment of this Act, and every 2 years
thereafter, provide to the Congress and each relevant Federal agency and make
publicly available—</text>
<subparagraph id="H5D7F5AEFCC7349EBA900771F0E8F42AC"><enum>(A)</enum><text>an up-to-date list
specifying each chemical identified by the Director to be a potential or actual
endocrine-disrupting chemical and identifying the level of evidence that the
chemical disrupts the human endocrine system, the level of concern that the
chemical disrupts the human endocrine system, and the pathways of exposure to
the chemical for humans and animals; and</text>
</subparagraph><subparagraph id="HF308140CA1674E289C37610E7A1A9DBB"><enum>(B)</enum><text>a report
on—</text>
<clause id="HA4CEFBE0E4D54BE1A84BA30FE13EDFA3"><enum>(i)</enum><text>the
National Toxicology Program’s activities pertaining to endocrine-disrupting
chemicals; and</text>
</clause><clause id="H11764971DBB1426683B1D3ED45EE28A1"><enum>(ii)</enum><text>the
activities of Federal agencies with respect to endocrine-disrupting chemicals,
including actions taken or expected to be taken pursuant to section 201.</text>
</clause></subparagraph></paragraph></subsection><subsection id="HC593E492070C422496BB37AE8A995C74"><enum>(b)</enum><header>Expert
panel</header>
<paragraph id="HAEA6D24A31FC4CAFAB6EFA5E4EB43DB6"><enum>(1)</enum><header>Appointment</header><text display-inline="yes-display-inline">The Director, in consultation with the
National Toxicology Program Board of Scientific Counselors (or any successor
board or committee), shall appoint the members of the Endocrine Disruption
Expert Panel (established under subsection (a)(2)) from among individuals
who—</text>
<subparagraph id="HECD7A5D0A960410B92573E4A6CF33204"><enum>(A)</enum><text display-inline="yes-display-inline">have established expertise in the field of
endocrine disruption research by publishing research in peer-reviewed
literature and have received Federal endocrine-research-related funding within
the 2 years preceding appointment under this subsection;</text>
</subparagraph><subparagraph id="H7861A3BCBAFB4A0FAEB1FBC3A06C5D2D"><enum>(B)</enum><text>provide assurances
they will perform their duties in a manner free of conflicts of interest, as
determined by the Director, including by complying with section 208 of title
18, United States Code; and</text>
</subparagraph><subparagraph id="HA58242652435403E940AA6B38056E60E"><enum>(C)</enum><text>represent diverse
disciplines, which may include endocrinology, developmental and neurological
biology, embryology, biochemistry, physiology, epidemiology, endocrine-driven
oncology, in vitro and computational toxicology, and medical research.</text>
</subparagraph></paragraph><paragraph id="H49C11D7FBEF84E25961146785933E5A4"><enum>(2)</enum><header>Duties</header><text>During
each of the 10 years following the date of the enactment of this Act, the
Expert Panel shall—</text>
<subparagraph id="H630A6AC2F575429C8D69B4385861A4D3"><enum>(A)</enum><text>consider, and
report to the Director on, issues related to identification, classification, or
evaluation of not more than 10 endocrine-disrupting chemicals or groups of
endocrine-disrupting chemicals;</text>
</subparagraph><subparagraph commented="no" id="HC88E705F86A147BFAB59D8124D54D966"><enum>(B)</enum><text>evaluate existing
research aimed at understanding the biological pathways in humans by which
endocrine-disrupting chemicals operate and identify future research priorities
as appropriate; and</text>
</subparagraph><subparagraph commented="no" id="H58E450AC518D469C84F01DF07783C100"><enum>(C)</enum><text>maintain a list
that identifies chemicals of concern for endocrine disruption effects and
includes findings, based upon peer-reviewed studies and other relevant data,
regarding—</text>
<clause commented="no" display-inline="no-display-inline" id="H3745652012924B8A9E75D28C6983D6B0"><enum>(i)</enum><text>whether a chemical
is a potential or actual endocrine-disrupting chemical;</text>
</clause><clause commented="no" id="H39280DAC5BDC47908ED747BB558C91FF"><enum>(ii)</enum><text>the level of
evidence that the chemical is or may be an endocrine-disrupting
chemical;</text>
</clause><clause commented="no" id="HDD641281C640487AACE00B555CBFCA69"><enum>(iii)</enum><text>the level of
concern that the chemical may disrupt the human endocrine system;</text>
</clause><clause commented="no" id="HD13304C1893D425881C8E2FF2BD959FE"><enum>(iv)</enum><text>the pathways of
exposure to the chemical for humans and animals; and</text>
</clause><clause commented="no" id="H6C707F3298084075AEF30B43E684A5B8"><enum>(v)</enum><text>the need for
additional data, assays, testing, or research to determine the level of concern
associated with the chemical’s potential to disrupt the human endocrine
system.</text>
</clause></subparagraph></paragraph><paragraph commented="no" id="H777A81446E784DB8B7519732B92BC0F9"><enum>(3)</enum><header>Report</header><text display-inline="yes-display-inline">The Expert Panel shall provide to the
Director and make publicly available a biennial report on the Panel’s
activities, including an up-to-date version of the list under paragraph
(2)(C).</text>
</paragraph></subsection><subsection id="HA6DE6E62F0A84371B5F216CCC3F963B6"><enum>(c)</enum><header>Petitions</header>
<paragraph id="H965870DC9289499081C8398CF64C08A5"><enum>(1)</enum><header>In
general</header><text>Any State, Tribe, local government, Federal agency, or
person may petition the Director—</text>
<subparagraph id="H7DF9B354C0824154979668D02090CC53"><enum>(A)</enum><text>to determine
whether a chemical should be identified by the National Toxicology Program to
be a potential or actual endocrine-disrupting chemical and included in the list
under subsection (a)(4)(A); or</text>
</subparagraph><subparagraph id="H8421C513F08C410E8B4BC4CD6A672E19"><enum>(B)</enum><text>to reclassify a
chemical, revise a finding, or amend any other determination of the National
Toxicology Program based upon new information.</text>
</subparagraph></paragraph><paragraph id="H00CB45EAB0D34B0FA36C28A6497C1699"><enum>(2)</enum><header>Rules</header><text>The
Director shall adopt rules that provide for—</text>
<subparagraph id="H2D73048B04BB49CBA59E7FB421FFA28E"><enum>(A)</enum><text>the form and
procedure for filing of petitions under paragraph (1); and</text>
</subparagraph><subparagraph id="H44054ADC114E444982ECD4F5BF28CAB9"><enum>(B)</enum><text>the procedural
rights of entities filing such petitions.</text>
</subparagraph></paragraph></subsection><subsection id="HBE2D8B5E32934445AFB809C94EBBFBCD"><enum>(d)</enum><header>No judicial
review</header><text>A listing, finding, or other determination under this
section shall not be subject to judicial review, nor to correction under
section 515 of the Treasury and General Government Appropriations Act, 2001
(commonly referred to as the <term>Information Quality Act</term>).</text>
</subsection></section><section id="H76D7CA59B0A74FD69E6EA754719DB128"><enum>102.</enum><header>Research
program of national institute of environmental health sciences</header><text display-inline="no-display-inline">Subpart 12 of part C of title IV of the
Public Health Service Act (42 U.S.C. 2851 et seq.) is amended by adding at the
end the following:</text>
<quoted-block id="H985A5EC465154C74937BDD7BD12DA1E0" style="OLC">
<section id="H31A7693FD1B04945970D0FC3BED4F626"><enum>463C.</enum><header>Endocrine
disruption research program</header>
<subsection id="HB87D864FC12E4A9B887BA35358B87183"><enum>(a)</enum><header>Program</header><text display-inline="yes-display-inline">The Director of the Institute shall conduct
and support a research program, to be known as the Endocrine Disruption
Research Program, to improve the understanding of how chemicals can disrupt the
human endocrine system. Such program shall—</text>
<paragraph id="HD76300FFB16E40F4974442C6E0DC6FDA"><enum>(1)</enum><text>be
designed—</text>
<subparagraph id="H0D743D6C5BB24621A5939AE52DB62F51"><enum>(A)</enum><text display-inline="yes-display-inline">to develop the information needed by
Federal agencies to understand chemical disruption of the endocrine system and
reduce human and animal exposure to endocrine-disrupting chemicals;</text>
</subparagraph><subparagraph id="H162FFDF09CE545B9A5EFE62339C9E0D1"><enum>(B)</enum><text>to understand the
cellular pathways in humans by which endocrine-disrupting chemicals are able to
cause adverse effects; and</text>
</subparagraph><subparagraph id="HAC83BE2F849A43B5920BD6CE40647B0A"><enum>(C)</enum><text>to use laboratory
practices that will produce data that are sufficiently accurate and
reproducible to be used for regulatory decisions;</text>
</subparagraph></paragraph><paragraph id="HE33934AD2A2A4036AB71DC6424AF107B"><enum>(2)</enum><text>include research
to design, develop, and validate appropriately sensitive tests to screen and
identify chemicals capable of disrupting the human endocrine system;</text>
</paragraph><paragraph id="HC3F79EC0FE1F4C8987F6E5E57DB3948B"><enum>(3)</enum><text>address the full
range of possible human health impacts, including but not limited to—</text>
<subparagraph id="H4FA6F3FDB66A4E06B0B30D8EDB8D98C1"><enum>(A)</enum><text>male and female
developmental and reproductive disorders;</text>
</subparagraph><subparagraph id="H47885846FBE44BC98F450621F77E578D"><enum>(B)</enum><text display-inline="yes-display-inline">brain and neurobehavioral disorders;</text>
</subparagraph><subparagraph id="HE4FDAE3A2EF94582BA912AA27BAE5D0D"><enum>(C)</enum><text>metabolic
syndrome, prediabetes, diabetes, improper glucose and fat metabolism, obesity,
and cardiovascular disorders;</text>
</subparagraph><subparagraph id="H31236CAFC8F547018E8EA04D2363CFBF"><enum>(D)</enum><text>effects on the
pituitary, hypothalamus, hippocampus, thyroid, adrenal, immune, bone,
cardiovascular, and other endocrine organs and systems throughout all life
stages;</text>
</subparagraph><subparagraph id="H982865E35D604F77BC2FDAB99667DFDE"><enum>(E)</enum><text>hormonally driven
cancer; and</text>
</subparagraph><subparagraph id="H90CD135F4D2C4D26A3B7158CC44CED93"><enum>(F)</enum><text>other related
effects;</text>
</subparagraph></paragraph><paragraph id="H78390A69AE35473A93587C054836F945"><enum>(4)</enum><text>consider the
potential for additive and synergistic effects;</text>
</paragraph><paragraph id="H6FB77E94A77349AB942E75A068182829"><enum>(5)</enum><text>be carried out
using a multidisciplinary approach to ensure connections among multiple levels,
including the molecular, organ, and whole animal or human levels;</text>
</paragraph><paragraph id="HB9BC8FDECEF64E2EBB7C6E9DDD44E194"><enum>(6)</enum><text>refine
computational modeling tools to integrate cellular pathway data into a
dose-response framework for risk assessment;</text>
</paragraph><paragraph id="H93B1C2964C734DE5B7C07BF855391B47"><enum>(7)</enum><text>identify
biomarkers of exposure and effect that can be further developed and translated
for use in human epidemiological and public health studies focused on defining
the role of endocrine-disrupting chemicals in disease etiology across the
lifespan; and</text>
</paragraph><paragraph id="HA28A7CCBE246422BACA0800E7A80FCB8"><enum>(8)</enum><text>ensure that
research or testing involving living animals is carried out only when equally
effective and reliable alternative approaches for obtaining the result sought
are not readily available.</text>
</paragraph></subsection><subsection id="HD61B482EC5024BA5B8A336BB4003BAE5"><enum>(b)</enum><header>Workshops and
fora</header><text>The Director of the Institute may conduct workshops and fora
and provide information on the health effects associated with chemicals that
may disrupt the endocrine system in order to—</text>
<paragraph id="H23A1C21B9F3A4AE68AAB13E78F5D2B08"><enum>(1)</enum><text>identify chemicals
for research under subsection (a);</text>
</paragraph><paragraph id="H1B6EC03310C24D6FBE269BC2CE73C217"><enum>(2)</enum><text>strategize on
approaches for the development of sensitive tests to screen chemicals for
endocrine-disrupting activity using assays;</text>
</paragraph><paragraph id="HF3E2EA31C36541A3AA6362ED40961237"><enum>(3)</enum><text>review the state
of the science on endocrine-disrupting chemicals and provide recommendations
for a research, testing, and training agenda; and</text>
</paragraph><paragraph id="H83D88A6DDD5D47BDADBD0C9646049B07"><enum>(4)</enum><text>educate attendees
about endocrine-disrupting chemicals.</text>
</paragraph></subsection><subsection id="H33A6C9BB92DC4D2E9F5E119E95A7A453"><enum>(c)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text>
<paragraph commented="no" id="H43A7B6635C154E3E91FE374EF764DD5F"><enum>(1)</enum><text display-inline="yes-display-inline">The term <term>chemical</term> means an
individual chemical, a combination of chemicals, or a mixture of
chemicals.</text>
</paragraph><paragraph id="H424DA6E7FF3F4B47B28FE3F1E6C2F005"><enum>(2)</enum><text>The term
<term>endocrine-disrupting chemical</term> means a chemical that interrupts,
alters, interferes with, disturbs, or otherwise changes the human or animal
endocrine system or its
functioning.</text>
</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><enum>II</enum><header>Reducing exposure
to endocrine-disrupting chemicals</header>
<section id="H07351E16F331496E9F72B1D5CE59D3E4"><enum>201.</enum><header>Federal agency
action</header>
<subsection id="H7DEBC2B447A5419B8DCD6F217399108E"><enum>(a)</enum><header>Response To list
and strategy</header>
<paragraph id="H8F867771A75B4609A611E7FB542CBEC6"><enum>(1)</enum><header>In
general</header><text>Not later than 90 days after receiving each biennial
list, strategy, and report under section 101(a)(4), each Federal agency with
regulatory authority over any chemical included on the list shall prepare and
publish a written response to the list and strategy.</text>
</paragraph><paragraph id="HC25D5B431012496EB6F3810F41D256B7"><enum>(2)</enum><header>Contents</header><text>At
a minimum, a Federal agency’s response under paragraph (1) shall—</text>
<subparagraph id="H60A4671C7A0A4AAD883A6DFA2A6564DB"><enum>(A)</enum><text>include an
evaluation of the findings and determinations of the National Toxicology
Program pertaining to each listed chemical subject to the agency’s regulatory
authority; and</text>
</subparagraph><subparagraph id="HA0BDE44100D340C4A65EE3AF1D40E384"><enum>(B)</enum><text>adopt or modify,
as scientifically appropriate, each finding of the National Toxicology Program
pertaining to—</text>
<clause id="H806F260570934F3496621E58AF8F4BDB"><enum>(i)</enum><text display-inline="yes-display-inline">whether any such chemical disrupts or may
disrupt the human endocrine system;</text>
</clause><clause id="H8B4D782C57684476BAA959567DD42FED"><enum>(ii)</enum><text>the
level of concern associated with any such chemical’s potential to disrupt the
human endocrine system; and</text>
</clause><clause id="H4622808D8E8D4151B5B857D762A0367A"><enum>(iii)</enum><text>the pathways of
exposure to the chemical for humans and animals.</text>
</clause></subparagraph></paragraph></subsection><subsection id="HCF2A98E1A4554B0C884A9BA78E2843CB"><enum>(b)</enum><header>Minimal level of
concern</header><text>If the Director finds under section 101(a)(3)(A) that
there is at least a minimal level of concern that a chemical may disrupt the
human endocrine system—</text>
<paragraph id="H0702F75CB6EB4C5183C766DB27FB7BDC"><enum>(1)</enum><text>each Federal
agency with regulatory authority over the chemical shall—</text>
<subparagraph id="H279BFA6B9F164ABD8C21EFAED0BF9DAD"><enum>(A)</enum><text>develop a strategy
for reducing human exposure to the chemical;</text>
</subparagraph><subparagraph id="H8A910ABB1E3140ED9C466E58F80E88A2"><enum>(B)</enum><text>make the strategy
publicly available not later than 180 days after the agency receives the
Director’s finding; and</text>
</subparagraph><subparagraph id="H7B54FC2B3D844429B317D5FEDF7EE728"><enum>(C)</enum><text>include in the
strategy methods to promote voluntary actions by industry for reducing human
exposure to the chemical; and</text>
</subparagraph></paragraph><paragraph id="H5C3FF0A618F14309B6BF3985F90DF245"><enum>(2)</enum><text>each Federal
agency with regulatory authority over the chemical shall take action under such
authority, such as further testing or issuance of orders, regulations, or
public notices, to reduce or eliminate human exposure to the chemical.</text>
</paragraph></subsection><subsection id="H25B58E4FFE764C4BBFBDCC5EE843EDA7"><enum>(c)</enum><header>Highest level of
concern</header>
<paragraph id="H95CC2F2F5A0A4572915EADE849579B94"><enum>(1)</enum><header>Prohibition</header><text>Beginning
on the date that is 24 months after the Director makes publicly available a
finding under section 101(a)(3)(B) that there is a high level of concern that a
chemical may disrupt the human endocrine system, it shall be unlawful to use
the chemical in a manner in or affecting interstate commerce unless the pathway
to human exposure is mitigated before or in conjunction with such use.</text>
</paragraph><paragraph id="H6FEBA9B0750544458DE36BB131C64C1C"><enum>(2)</enum><header>Federal agency
action</header><text display-inline="yes-display-inline">Not later than 24
months after the Director makes publicly available such a finding under section
101(a)(3)(B), each Federal agency with regulatory authority over the chemical
subject to the finding shall establish regulations or take other actions to
implement the prohibition in paragraph (1) with respect to such
chemical.</text>
</paragraph></subsection><subsection id="H6354161EB6A94E98AD482C7E7A5C83A6"><enum>(d)</enum><header>Aggregated
computational toxicology resources databases</header><text>The Administrator of
the Environmental Protection Agency shall include the findings and
determinations of the National Toxicology Program pertaining to
endocrine-disrupting chemicals in the Aggregated Computational Toxicology
Resource (ACToR) databases (or any successor databases) to the extent otherwise
permitted by law including any restrictions on the disclosure of confidential
business information.</text>
</subsection></section><section id="HA8CE3CB8963B475DA551BC5EB5F2E76F"><enum>202.</enum><header>Citizen
suits</header>
<subsection id="HE79BBEB0C1A843CCB779C5E6EA4E0228"><enum>(a)</enum><header>Authority To
Bring Civil Actions</header><text>Any State, Tribe, local government, or person
may commence a civil action to prevent or restrain a prohibited use of a
chemical in violation of section 201.</text>
</subsection><subsection id="H605926396D3D4270A00627E1C2E03FE4"><enum>(b)</enum><header>Jurisdiction</header><text>The
United States courts of appeal shall have exclusive original jurisdiction over
such action.</text>
</subsection></section><enum>III</enum><header>Training</header>
<section id="H30CED2CD5E5546DDADEFCC60E3324B1D"><enum>301.</enum><header>Training in
fields related to the prevention of endocrine disruption</header><text display-inline="no-display-inline">The Director shall establish a program to
support, directly or by making grants, graduate and postdoctoral training in
fields related to the study and prevention of endocrine disruption.</text>
</section><enum>IV</enum><header>Miscellaneous</header>
<section id="H7E9B7393C54C46A4966C10017FB627B2"><enum>401.</enum><header>Authorization
of appropriations</header><text display-inline="no-display-inline">To carry out
this Act and the amendments made by this Act, there are authorized to be
appropriated such sums as may be necessary for fiscal years 2012 through
2021.</text>
</section>